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Introduction: HIV infection and its therapy which can affect their aerobic capacity and health-
related quality of life of patients.
Objective: We conducted a cross-sectional study to determine if aerobic capacity and
health related quality of life was decreased in HIV-infected patients receiving highly active
antiretroviral therapy and comparing patients with and without lipodystrophy.
Research design and methods: HIV-infected patients older than 18 years, and in current use
of  highly active antiretroviral therapy drugs, were evaluated for blood count, fasting total
cholesterol, high density lipoprotein, triglycerides, glucose, HIV viral load and CD4/CD8
counts, body composition, peak oxygen consumption (peak VO2) and metabolic equiva-
lent. Health related quality of life was assessed by using Short Form-36 (SF-36). Statistical
analysis was carried out using SPSS version 20.0.
Results: A total of 63 patients with mean age of 43.1 ± 6.4 years were evaluated, of these 34
(54%) had lipodystrophy. The average peak VO2 (31.4 ± 7.6 mL kg−1 min−1) was signiﬁcantly
lower (p < 0.01) than expected values (37.9 ± 5.6 mL kg−1 min−1) according to the character-
istics of the patients. The lipodystrophy group presented with a signiﬁcant difference in
muscle  mass, body fat, peak VO2 and metabolic equivalent and in functional capacity
domains of SF-36.
Conclusion: Aerobic capacity values were reduced in HIV-infected patients under highly
active antiretroviral therapy when compared to predicted values. Lipodystrophy was asso-ciated with reduced aerobic capacity and higher frequency of metabolic syndrome. Lifestyle
modiﬁcation should be a priority in the management of chronic HIV disease.
©  2015 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author at: Departamento de Biofuncão, Curso de Fisiote
da  Saúde, Av. Reitor Miguel Calmon, s/n – Vale do Canela, CEP 40.110-1
E-mail address: mansueto.neto@ufba.br (M. Gomes Neto).
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IV-infected individuals are living longer in the era of highly
ctive antiretroviral therapy (HAART). However, recent reports
uggest increased rates of cardiovascular risk,1,2 body fat
hanges (lipodystrophy),3 and long-term adverse effects such
s changes in physical functioning, disabilities and health-
elated quality of life (HRQOL) are common ﬁndings in this
opulation.4
Functional impairment is common among HIV-infected
ersons. HIV-related disability has been associated with
ecrease in exercise capacity and patient’s daily activities.5,6
educed aerobic capacity or cardiovascular ﬁtness may
ontribute to further physical impairment and activity lim-
tations, placing HIV-infected patients at risk for poor
ealth outcomes.7–9 Some studies have shown an association
etween cardiovascular ﬁtness and cardiovascular mortal-
ty, as well as all-cause mortality in men  and women of all
ges.10,11
Dependence on assistance with activities of daily living
nd/or reduced recreational activities participation may be
ssociated with a lower HRQOL and higher risk of mortality.12
owever, conﬂicting results have been reported in regard to
erobic capacity. Some authors have reported reduced aerobic
apacity in HIV patients in HAART use,5,6,12,13 whereas others
ave detected no adverse long-term effect.14,15
The measure of peak oxygen consumption (peak VO2) has
een utilized to assess aerobic capacity as well as for the pre-
cription of exercise programs in this population.16 HRQOL is
ne of the most utilized subjective aspects in evaluating the
mpact of chronic diseases and both its deﬁnition and assess-
ent are contentious.17,18 The combination of negative effects
n physical and mental function in HIV-infected patients with
ipodystrophy may have a further adverse impact on HRQOL,
ut its impact on aerobic capacity and quality of life has not
een properly studied. The objective of this study was to deter-
ine if aerobic capacity and quality of life was diminished in
IV-infected patients receiving HAART and if lipodystrophy
as related to these outcomes.
ethods
atients and settings. The study was conducted at the AIDS
linics of Federal University of Bahia Hospital (HUPES), a pub-
ic HIV referral service in Salvador, Brazil. The project was
pproved by the Institutional Ethics Research Committee.
Study design:  We  conducted an observational cross-
ectional study. Patients were consecutively invited to enter
he protocol following the signature of an informed con-
ent. The inclusion criteria were: current use of ARV drugs,
ge equal or higher than 18 years, and availability to attend
he study activities. Exclusion criteria included pregnancy,
ctive opportunistic infections and history of regular exercis-
ng before entering the study.easures
aboratory measurements consisted of total cholesterol, HDL,
riglycerides, glucose, HIV viral load and CD4/CD8 counts. 1 6;2  0(1):76–80 77
Metabolic syndrome was deﬁned following National Choles-
terol Education Program Adult Treatment Panel III deﬁnition.19
Based on that deﬁnition, three or more  of the following crite-
ria need to be met  for deﬁning metabolic syndrome: (1) fasting
serum triglycerides ≥150 mg/dL; (2) abnormal waist circumfer-
ence: waist perimeter ≥102 cm in man, or ≥88 cm in women;
(3) fasting blood glucose ≥100 mg/dL; (4) hypertension: systolic
blood pressure ≥130 mmHg  and/or diastolic blood pressure
≥85 mmHg, and/or use of an antihypertensive drug; (5)
low HDL-cholesterol: ≤40 mg/dL for men, or ≤50 mg/dL for
women.
We measured weight, height, body mass index (BMI) and
skin fold. Body weight was measured using a balance accurate
to 100 g. Height was measured by a stadiometer with sub-
jects barefoot. BMI was calculated by dividing body weight
(kg) by height squared (m2). We  used the digital caliper to
evaluate the percentage of lean body mass, fat mass, and
muscle mass. The calculation was based on Faulkner’s skin-
fold protocol.20 In addition, we measured the circumference
of chest, waist, waist-hip ratio, abdomen, hips, forearms,
arms, thighs and calves (0 and 6 months). The measure-
ment was performed with the patient standing upright,
using a ﬂexible tape measure and extendable to one decimal
place.21,22
Lipodystrophy was deﬁned clinically by physical examina-
tion and by patient report of fat wasting in the face, arms
or legs with or without central obesity. Patients were initially
asked a general question about any changes in body appear-
ance, followed by questions with speciﬁc reference to the
regions mentioned above, time of onset of changes in each
region, and whether the changes had resolved. Patients with
weight change but without peripheral fat loss were not deﬁned
as having lipodystrophy.23
The exercise testing was performed to evaluate the clin-
ical response, the hemodynamic, electrocardiographic and
metabolic stress, and to customized exercise prescription and
subsequent evaluation of therapeutic intervention, under the
supervision of a cardiologist. We  used the ergometer treadmill.
We chose ramp protocol for the study. Subjects were exercised
on a motor-driven treadmill with an initial speed of 3 km h−1
and a 2% incline. We used continuous increments in speed and
incline, following a ramp protocol adjusted to the subjects’
predicted functional capacity, to reach volitional fatigue in
approximately 8–12 min. Blood pressure was measured every
3 min  using a standard arm sphygmomanometer, while 12-
lead ECG was continuously monitored.24,16 The values of the
test performed were compared with the predicted values in
accordance with Jones equation for the treadmill test (VO2 pre-
dicted for male subjects = [60.0 − (0.55 × age)] × 1.11; and VO2
predicted for female subjects = [48.0 − (0.37 age)] × 1.11).16
Assessment of quality of life was performed by applying the
SF-36 (Medical Outcomes Study 36-Item Short-Form Health
Survey). The SF-36 questionnaire contains 36 questions that
are grouped into eight domains: functional capacity, limita-
tions related to emotions, and perceptions of mental health,
whose scores range from 0 to 100, where zero corresponds to
the worst general state of health and 100 to the best state,
meaning that the higher the total score, the better the percep-
tion of quality of life. This tool was already validated for use
in Brazilian patients.25
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Table 1 – Demographic and clinics characteristics of the
HIV infected patients included in study.
Study group (n = 63)
Age (yr) 43.1 ± 6.4
Gender (male:female) 34:29
Ethnicity (white:nonwhite) 27:36
Lyposdistrophy (yes:no) 34:29
Metabolic syndrome 24:39
Body weight (kg) 63.3 ± 11.2
Muscle mass 55.2 ± 10.5
Body mass index (kg m−2) 23.1 ± 3.45
Hip 95.6 ± 7.1
Waist-to-hip ratio 0.8  ± 0.1
Body fat (%) 21.3 ± 8.6
CD4+ (cell mm−3) 539.7 ± 291.8
Triglycerides (mg dL−1) 185.6 ± 102.1
Total cholesterol (mg dL−1) 207.3 ± 64.1
HDL cholesterol (mg dL−1) 48.9 ± 19.8
Glucose (mg dL−1) 90.2 ± 15.3
Hemoglobin (g dL−1) 13.4 ± 1.3
−1 −1
Table 2 – Demographic and clinics characteristics of
patients with lipodystrophy compared with no
lipodystrophy.
Lipodystrophy
group
n  = 34
No lipodystrophy
group
n = 29
Age 44.9 ± 8.9 40.8 ± 9.6
Gender (male:female) 18:15 16:14
Body mass index (kg m−2) 23.0 ± 4.5 23.1 ± 2.0
Muscle mass 49.2 ± 10.2 55.6 ± 11.8*
Body fat (%) 27.6 ± 11.8 19.9 ± 7.3*
Waist 81.4 ± 11.7 80.9 ± 6.9
Hip 95.82 ± 9.17 95.53 ± 4.74
CD4+ (cell mm−3) 490.4 ± 25.,6 597.6 ± 320.3
Triglycerides (mg dL−1) 197.3 ± 88.1 172.4 ± 118.2
Total cholesterol (mg dL−1) 217.8 ± 79.9 194.6± 35.2
HDL cholesterol (mg dL−1) 52.4 ± 22.8 44.2±  14.6
Glucose (mg dL−1) 90.2± 18.4 90.3±  10.5
Metabolic syndrome
(yes:no)
19:15 8:21*
Peak VO2 (mL kg−1 min−1) 31.4 ± 6.1 30.4 ± 7.6*
MET 9.3 ± 1.8 8.7 ± 2.2*
of HAART such as congestive heart failure, coronary artery dis-Peak VO2 (mL kg min ) 31.4 ± 7.6
MET 8.7 ± 2.1
Statistical  analysis
Data of continuous variables were analyzed by using measures
of central tendency and dispersion, and expressed as mean
and standard deviation. Categorical or dichotomous variables
were analyzed by using measures of frequency. We performed
statistical tests Shapiro–Wilk to evaluate normality for all vari-
ables. Student’s t test or Mann–Whitney test were used to
compare the mean differences of variables between the lipos-
dystrophy occurrences. Chi-square test was used to compare
proportions. All p values were 2-tailed, and statistical signif-
icance was set at .05. All calculations were performed with
Statistical Package for Social Sciences – SPSS version 20.0.
Results
A total of 70 patients were invited, however seven patients did
not attend the evaluations. Sixty-three evaluated patients had
mean age of 43.1 ± 6.4 years. Table 1 shows the demographic
and clinics characteristics of patients in the study.
Treadmill testing results showed a mean peak VO2 ± SD
of 31.4 ± 7.6 mL  kg−1 min−1. The average peak VO2
was signiﬁcantly lower (p < 0.01) than expected values
(37.9 ± 5.6 mL  kg−1 min−1) according to the Jones equation.16
Patients were stratiﬁed by elapsed time since HIV diagno-
sis (±5 years). No differences were found for demographic
characteristics and age (p > 0.05). The time since HIV diag-
nosis was also a factor that inﬂuenced the aerobic capacity
of the patients. Patients with more  than 5 years since diag-
nosis of HIV infection showed lower aerobic capacity than
patients with less than 5 years of HIV (30.3 ± 7.5 versus
34.7 ± 7.02 mL  kg−1 min−1, p = 0.04).
54% of the patients had lipodystrophy. Demographic vari-
ables were comparable between groups with and without
lipodystrophy.
Lipodystrophy group presented with a signiﬁcant differ-
ence in muscle mass, body fat, peak VO2 and MET compared∗ p < 0.05.
with patients without fat changes. This indicates that patients
with lipodystrophy have less muscle mass and aerobic capac-
ity in addition to a higher percentage of body fat. Table 2
displays demographic characteristics of patients according to
the occurrence of lipodystrophy.
In lipodystrophy group, 56% of patients had a previous diag-
nosis of metabolic syndrome (56%) versus only 27% in the
group without lipodystrophy (p < 0.05).
Table 3 shows the results of HRQOL of patients according
to the presence of lipodystrophy. The domains of SF-36 that
had lower values were pain, vitality, general health and men-
tal health. Considering the HRQOL among patients with and
without lipodystrophy only the domain functional capacity
presented reduction in the group with lipodystrophy com-
pared with no lipodystrophy.
Discussion
Our results demonstrate that aerobic capacity values were
reduced in HIV-infected patients under HAART when com-
pared to predicted values. The prevalence of lipodystrophy
in this study was 54%. Patients with lipodystrophy exhibited
a signiﬁcant reduction in muscle mass and aerobic capacity
compared to those without such fat changes.
In a systematic review of Brazilian studies on lipodystro-
phy, the weighted average of the prevalence of lipodystrophy
in people living with HIV was 53.5%26 and physical activity
was considered an independent protective factor against the
onset of HIV-associated lipodystrophy.
Several possible mechanisms for decline in aerobic capac-
ity and activity limitation in people with HIV have been
reported. Comorbidities that may be associated with the useease, peripheral vascular disease, and stroke may lead to a loss
of physical function.27 As a result of associated comorbidities
and related phenomena (such as loss of lean muscle mass and
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Table 3 – Quality of life of HIV-infected patients included in study and with lipodystrophy compared with no
lipodystrophy.
Domains SF-36 HIV-infected patients Lipodystrophy group No lipodystrophy group
Functional capacity 71.1 ± 25.4 61.76 ± 24.02* 77.76 ± 24.03
Physical limitation 81.4 ± 20.8 80.15 ± 33.58 82.76 ± 27.63
Pain 42.3 ± 9.5 43.18 ± 8.58 41.24 ± 10.56
General health 61.0 ± 20.6 62.35 ± 18.97 59.41 ± 22.64
Vitality 58.0 ± 15.6 58.97 ± 14.86 56.90 ± 16.71
Social aspects 80.6 ± 21.2 81.31 ± 19.82 79.36 ± 22.72
Emotional limitation 78.2 ± 33.8 78.04 ± 34.10 78.30 ± 34.07
Mental health 60.2 ± 12.9 62.47 ± 11.22 57.52 ± 14.47
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ain), individuals often reduce their physical activities, which
ay further decrease tolerance to exercise and quality of life.28
Structural and inﬂammatory muscle abnormalities which
ay impair the muscle’s ability to extract or utilize oxygen
uring exercise also can also be associated with the physical
imitation. Raso et al.15 observed that poor muscle strength is
bserved in some HIV/AIDS patients, which is associated with
ower anaerobic power and peak oxygen uptake (peak VO2).
owever, the peak VO2 of physically active HIV patients does
ot differ from that observed in controls of similar age and
ith similar physical activity patterns.15
Røge et al.29 have identiﬁed that the signiﬁcantly lower
orking capacity and the trend toward reduced peak VO2
n HIV-infected patients with lipodystrophy could be caused
y mitochondrial dysfunction, but may also be caused by
mpaired physical ﬁtness caused by underlying chronic dis-
ase.
In study performed for Zonta et al.,30 among the 120 HIV-
nfected patients, 85% reported impaired physical activity, 70%
f the patients complained about various degrees of weakness,
0% stated that they performed all of their regular activities,
lthough at a slower pace, with pauses for resting; 42% admit-
ed that they had problems in making larger efforts and 8% felt
ike lying in bed. Functional status and the disability evalua-
ions were associated with alterations in muscular strength.
Physiological deconditioning also may play a role in activity
ntolerance in HIV-infected patients, but this fact alone could
ot have fully accounted for the severity of the limitation or
he fatigue-mediated functional limitations associated with
IV infection.31 Cade et al.32 report that the musculature’s
bility to extract and utilize oxygen accounts for peak aerobic
xercise dysfunction in individuals with asymptomatic HIV
nfection and that HAART, rather than deconditioning alone,
ppears to limit peak aerobic capacity.
The assessment of the quality of life is an essential out-
ome in rehabilitation process, and it is of utmost importance
o understand how HIV-infected patients live. It is known that
RQOL is related to mental and physical status.33 Erlandson
t al.34 evaluated the impact of physical function impairments
n quality of life in 359 HIV-infected patients and it was
bserved that the faster gait speed, chair rise time, and greater
hysical activity were associated with greater quality of
ife.34
Blanch et al.35 evaluated 84 HIV-infected patients with
ipodystrophy and reported a poorer physical status incomparison with those without lipodystrophy. However, the
lipodystrophy itself was not found to inﬂuence overall qual-
ity of life. This result is in agreement with the present study
that also found no signiﬁcant difference in the domains of
quality of life between patients with and without lipodystro-
phy, with the exception of functional capacity domain that
was most impacted on lipodystrophy group. Blanch et al. con-
clude that the impact of HIV-related lipodystrophy on quality
of life depends on certain patient characteristics, rather than
on the presence of lipodystrophy itself.35
There are a number of limitations to our data. Unfortu-
nately, we were unable to measure the level of activity of
our patients. The reduction in the level of activity may be a
factor associated with the reduction of aerobic capacity. How-
ever, since patients were included if they were not engaged
in regular exercising before the beginning of the research,
they supposedly had similar level of prior activity. It should
also be emphasized that our patient sample was deliberately
selected in terms of a number of criteria for good health such
as be aware, be independent, and be able to walk to hospi-
tal. We  used digital caliper to evaluate the percentage of lean
body mass, fat mass, and muscle mass, which is less pre-
cise than more  sophisticated methods like, dual energy X-ray
absorptiometry. Although we did not use imaging resources
to quantify fat tissue, clinical evaluation by physical exam-
ination is also considered a reliable method to diagnosis
lipodystrophy.23,35 The lack of a control group with HIV nega-
tive is also a limitation, because it does not allow us to assess
the magnitude of the impact of HIV on quality of life.
Conclusion
HIV reduces the aerobic capacity. The presence of lipodys-
trophy was associated with reduced aerobic capacity, muscle
mass and higher frequency of metabolic syndrome. Lipodys-
trophy does not seem to inﬂuence overall HRQOL. Lifestyle
modiﬁcation should become a greater priority in the manage-
ment of chronic HIV disease.Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
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